Scarica l'app Stockscreener
5.31
0.19%
0.03
Dopo l'orario di chiusura:
5.31
Precedente Chiudi:
$5.34
Aprire:
$5.34
Volume 24 ore:
20,639
Relative Volume:
0.36
Capitalizzazione di mercato:
$166.27M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-1.9101
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-3.43%
1M Prestazione:
-3.60%
6M Prestazione:
-42.29%
1 anno Prestazione:
+19.69%
Intervallo 1D:
$5.25
$5.5899
Intervallo di 1 settimana:
$5.25
$5.96
Portata 52W:
$4.31
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
5.31 | 166.27M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Yahoo Finance
(ACRV) Trading Signals - Stock Traders Daily
Brokers Set Expectations for ACRV FY2024 Earnings - MarketBeat
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - MSN
Acrivon Therapeutics Inc (ACRV) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Acrivon Therapeutics announces FDA granted BDD for ACR-368 - Yahoo Finance
Research Analysts Offer Predictions for ACRV FY2024 Earnings - Defense World
The -10.05% Simple Moving Average of Acrivon Therapeutics Inc’s (ACRV) Stock in the Past 200 Days - The News Heater
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status - Insider Monkey
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
ACR-368 OncoSignature assay gains FDA breakthrough status - MSN
12 AI News and Ratings Investors are Keeping Their Eye On - Insider Monkey
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer - MSN
Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation - Marketscreener.com
Acrivon Therapeutics, Inc. Announces FDA Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - Marketscreener.com
Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification - Marketscreener.com
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
ACR-368 OncoSignature assay gains FDA breakthrough status By Investing.com - Investing.com UK
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 - The Bakersfield Californian
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated at KeyCorp - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Research Coverage Started at Cantor Fitzgerald - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at KeyCorp - Defense World
Head-To-Head Analysis: Jazz Pharmaceuticals (NASDAQ:JAZZ) & Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 6.3% - MarketBeat
JPMorgan Chase & Co. Has $238,000 Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight -January 31, 2025 at 08:14 am EST - Marketscreener.com
(ACRV) Trading Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average PT from Brokerages - Defense World
Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 6.3% in December - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(ACRV) On The My Stocks Page - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Growth in Short Interest - MarketBeat
Geode Capital Management LLC Has $2.12 Million Stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Investment Report - Stock Traders Daily
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
State Street Corp Acquires 47,233 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Brokerages - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Sells 27,705 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acrivon Therapeutics Inc Azioni (ACRV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 11 '24 |
Buy |
8.50 |
2,353,000 |
20,000,500 |
5,360,858 |
2.95%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):